If it wasn't 'Regal funds management' reducing their position to 6.66% we would have been well over 10c by now imo.
Australian Ethical investments staying firm with their 10.49% holding , i see them as more attuned to a biostock investment than Regal funds management. Multi Multi millionaire Chris Retzos holding firm with 7% of PTX. One Managed Investment Funds Limited (Ti Growth A/C) holding 1.35% .Top 20 holding over 40% which is a decent amount for a speculative biotech imo.
Results to date are very encouraging plus much more to come. Im staying in despite the temporary market jitters , there is more upside than downside longer term.
Prescient Managing Director and CEO Steven Yatomi-Clarke said, “Roche’s Phase 3 Akt inhibitor, ipatasertib – being tested in a different subset of breast cancer, metastatic triple negative disease - recently demonstrated three things that are very relevant to Prescient.
Firstly, the Akt pathway is activated in response to chemotherapy in breast cancer patients. Secondly, Akt inhibitors enhance the killing of breast cancer cells. Thirdly and most significantly, this Akt inhibition results in clinical benefit for breast cancer patients3.”
“This demonstrates that Akt inhibition can make a clinical difference to breast cancer patients, which is what Prescient is seeking to demonstrate in these studies. Further, we believe that PTX-200’s unique mechanism of action as a PH domain inhibitor may have advantages over other Akt inhibitors.” “It is worth noting that two of the people involved in the discovery and development of ipatasertib at Array BioPharma both now work in key roles with Prescient: our Vice President of Chemistry, Manufacturing and Controls, Dr Mike Preigh and our Vice President for Business Development Dr Jim Winkler. They both continue to provide significant insights that are very valuable in our own program,” Mr Yatomi-Clarke added.
2019 should be a turnaround year for PTX . It has all the right ingredients.
PTX Price at posting:
6.5¢ Sentiment: Buy Disclosure: Held
